Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals.

"Declarations Ethics approval and consent to participateThe study was reviewed and the need for approval was waived by the board of the Medical Ethics Committee of the VU Medical Center, Amsterdam UMC. All participants gave informed consent before participation. Consent for publicationNot applicable. Competing interestsHH, AG, TH, FM, AK, and MK report no financial disclosures or conflicts of interest. AH Research is funded by Alzheimer Nederland and the VUmc fund. AH is a consultant to Roche Diagnostics. All funding is paid to her institution. HRM performs contract research for Combinostics; all funding is paid to her institution. WF Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health ~ Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc, and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF is a consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. WF is a member of the steering committee of PAVE, and Think Brain Health. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is an associate editor at Brain. Leonie Visser (LNCV) has been an invited speaker at Schwabe Group, fees were paid to her institution. Competing interests HH, AG, TH, FM, AK, and MK report no financial disclosures or conflicts of interest. AH Research is funded by Alzheimer Nederland and the VUmc fund. AH is a consultant to Roche Diagnostics. All funding is paid to her institution. HRM performs contract research for Combinostics; all funding is paid to her institution. WF Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health ~ Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc, and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF is a consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. WF is a member of the steering committee of PAVE, and Think Brain Health. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is an associate editor at Brain. Leonie Visser (LNCV) has been an invited speaker at Schwabe Group, fees were paid to her institution."

"Funding The first author of this manuscript, HH, is appointed at the EU-FINGERS project, which is an EU Joint Programme—Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the guidance of JPND — www.jpnd.eu: Finland, Academy of Finland; Germany, Federal Ministry of Education and Research; Spain, National Institute of Health Carlos III; Luxemburg, National Research Fund; Hungary, National Research, Development and Innovation Office; The Netherlands, Netherlands Organisation for Health Research and Development (ZonMW #733051102), and; Sweden, Swedish Research Council. AH is a recipient of the Alzheimer Nederland Impulssubsidie (WE.06-2021-06). FM and MK are also supported by EU-FINGERS. FM is supported by Alzheimerfonden Sweden; ERA PerMed, which is funded under the ERA-NET Cofund scheme of the Horizon 2020 Research and Innovation Framework Programme of the European Commission Research Directorate-General, Grant Agreement No. 779282. MK is supported by Swedish Research Council; Center for Innovative Medicine (CIMED) at Karolinska Institutet; Region Stockholm (ALF, NSV) grants; Knut and Alice Wallenberg Foundation; Stiftelsen Stockholms sjukhem. FM and MK are recipients of a grant for the LETHE-Project, and LNCV was financially supported by this grant. The LETHE-Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 101017405 (https://cordis.europa.eu/project/id/101017405). AK was supported by the National Brain Research Program 3 (NAP2022-I-9/2022) of the Hungarian Academy of Sciences. HRM is a recipient of the Memorabel Dementia Fellowship 2021 (ZonMw projectnumber 10510022110004) and Alzheimer Nederland InterACT grant (projectnumber WE.08-2022-06). The collaboration project Dementia diagnostics using Artificial Intelligence (DAILY; project number LSHM19123-HSGF) is co-funded by the public–private partnership allowance made available by Health-Holland, Top Sector Life Sciences and Health, to stimulate public–private partnerships and Combinostics. WF, LNCV, and ES are recipients of ABOARD (A Personalized Medicine Approach for Alzheimer’s Disease); a public–private partnership receiving funding from ZonMW (#73305095007) and Health ~ Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. WF and ES are recipients of TAP-dementia, a ZonMw-funded project (#10510032120003) in the context of the Dutch National Dementia Strategy. LNCV is supported by fellowship grants from Alzheimer Nederland (WE.15–2019-05 and WE.08–2022-10) and the Amsterdam Public Health Research Institute. Research of Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The clinical database structure was developed with funding from Stichting Dioraphte. The chair of Wiesje van der Flier is supported by the Pasman stichting."